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Strengths and limitations of this study
 ► This is one of the first studies of the impact of ket-
amine on suicidal ideation based on qualitative in-
vestigation of patients’ experiences.
 ► Participants comprised a heterogeneous group in 
terms of gender, age, and number and routes of 
treatments with ketamine.
 ► The study is limited by the relatively small number 
of participants.
 ► Suicidal ideation was identified through a single 
item on a depression scale.
 ► Some patients declined participation.
ABSTRACT
Objective It is recognised that ketamine treatment can 
reduce suicidal ideation (SI) in people with depression, at 
least in the short term. However, information is lacking on 
patients’ perspectives on such effects. Studying these can 
contribute to greater understanding of the mechanisms 
underlying impact of ketamine treatment on SI. The aim 
of this study was to investigate patients’ reports of the 
impact of treatment on their SI, the duration of effects and 
possible mechanisms.
Design and setting This qualitative study consisted of 
semi-structured interviews with patients who had received 
ketamine treatment for depression. Interview data were 
analysed thematically.
Participants Fourteen patients (8 females, 6 males, 
aged 24–64 years) who had received treatment with 
ketamine for treatment-resistant depression, and had 
SI at the initiation of treatment. Two participants also 
had a diagnosis of bipolar type 1 and two of emotionally 
unstable personality disorder. Eight had a history of self-
harm.
Results SI reduced following ketamine treatment in 12 
out of 14 participants for periods of a few hours following 
a single treatment to up to three years with ongoing 
treatment. Reduction of SI was variable in terms of extent 
and duration, and re-emergence of suicidal thoughts 
often occurred when treatment ceased. Participants’ 
accounts indicated that reduced SI was associated with 
improved mood and reduced anxiety, as were clarity of 
thought, focus and concentration, and ability to function. 
Participants reported experiencing some or all of these 
effects in various orders of occurrence.
Conclusion Generally, ketamine treatment was 
experienced as effective in reducing SI, although duration 
of effects varied considerably. Patients’ perspectives 
indicated similarities in the mechanisms of reduction in SI, 
but some differences in their manifestation, particularly in 
relation to chronology. Experiences of this cohort suggest 
that reduced anxiety and improvement in ability to think 
and function were important mechanisms alongside, or 
in some cases independently of, improvement in mood. 
Further studies of patients’ experiences are required to 
gain enhanced understanding of the variability of effects of 
ketamine on SI and functionality.
InTRODuCTIOn
Suicide is a major public health problem glob-
ally.1 It often occurs in the context of depres-
sion.2 3 While both pharmacological and 
psychological treatments can reduce depres-
sion and suicidality,4 there is an important 
group of individuals who have treatment-re-
sistant depression in whom suicidal thinking 
is common and who have increased risk of a 
suicidal act.5 Ketamine has received increasing 
attention as a rapid-acting antidepressant, 
with studies suggesting that a single low-dose 
infusion has a beneficial although transitory 
effect for patients with depression, including 
treatment-resistant unipolar and bipolar 
depression.6–8 Multiple mechanisms have 
been described for the antidepressant action 
of ketamine: NMDA antagonism, reduced 
inhibitory interneuron GABAergic transmis-
sion, a glutamate surge, an AMPA-mediated 
increase in BDNF release and mTOR-depen-
dent neuroplasticity.9 In terms of beneficial 
effects of ketamine on suicidality there are 
several potential pathways, but the effects on 
the glutaminergic system may predominate.10
There is accumulating evidence from clin-
ical and randomised controlled trials (RCTs) 
that ketamine can reduce suicidal ideation 
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(SI), at least in the short term.11–13 However, there is 
uncertainty as to the mechanisms which might underlie 
this effect.14 Reduction in SI mediated by improvement 
in overall depressive symptoms may be one factor,15 but 
it also seems that improvements can occur independently 
from changes in mood.16–18
As far as we are aware, research to date has not exam-
ined patient views regarding the impact of ketamine 
treatment on SI or sought to understand how patients 
think that ketamine has reduced their SI. The aim of this 
qualitative study was to explore patients' perspectives on 
the impact of ketamine treatment on SI in the context of 
treatment-resistant depression, including perceived bene-
fits and how these might occur.
MeThOD
Participants
Inclusion criteria consisted of a diagnosis of unipolar 
or bipolar treatment-resistant depression, age 18 years 
or over, English speaking and SI at commencement 
of ketamine treatment. All participants had received 
ketamine treatment within the past year apart from one 
who had last received it 22 months prior to interview. SI 
was assessed by a score of 1 or above on the SI question 
of the Beck Depression Inventory (BDI).19 Exclusion 
criteria were a lack of mental capacity, significant impair-
ment of intellectual functioning and lack of fluency in 
spoken English. Participants were in receipt of a range 
of other antidepressant, anxiolytic, mood stabiliser and 
psychological treatments, which were not prescribed by 
the ketamine clinic.
Recruitment
All participants were recruited from a UK ketamine 
clinic. Standard treatment at this clinic is an initial three 
intravenous ketamine treatments (infusions) (0.5 mg/kg) 
followed by oral ketamine or a combination of oral and 
intravenous treatments as needed.
Forty eligible participants were approached by the 
ketamine clinic staff (HT and RM) by email or in person 
at the clinic. Participant information sheets were provided 
and interested individuals were referred to the researcher 
(KL), who then provided further information before 
undergoing the informed consent process (see the online 
supplementary appendix for further information in the 
completed Consolidated Criteria for Reporting Qualita-
tive Research Checklist). Patients approached included 
both those who had responded positively to ketamine 
treatment and patients who had not experienced any 
tangible benefit or who had stopped treatment due to 
side effects.
Data collection
Data collection was through one-to-one semistruc-
tured interviews carried out by the researcher (KL) at 
the hospital site where the ketamine clinic is based. All 
interviews were carried out face to face, although two 
longer interviews were carried out in two parts, with the 
second parts by phone or Skype. Topics included history 
of depression and suicidality, the circumstances under 
which participants started ketamine treatment, their 
experiences of treatment and perspectives on impact 
of ketamine on mood and SI. In addition, participants 
were asked to complete the BDI before the interview 
commenced (only the pretreatment score was used to 
determine eligibility). They also completed benefits 
and side effects checklists during the interview to gather 
structured information about frequency and duration of 
effects.
The length of interviews ranged from 1 to 2.5 hours. All 
interviews were tape recorded. Participants were advised 
that they could withdraw from the study at any time and 
provided with information about sources of support in 
case they became distressed following the interview.
Analysis
Interview data were transcribed verbatim and participants 
were given the opportunity to review their anonymised 
transcripts. Six participants took up this opportunity but 
none suggested changes. Thematic analysis was carried 
out to report participants’ experiences, meanings and 
realities using an inductive and semantic approach, 
following the six stages of analysis recommended by 
Braun and Clarke20: (1) becoming familiar with the data; 
(2) generating initial codes; (3) searching for themes; (4) 
reviewing themes; (5) defining and naming themes; and 
(6) write-up. Final identification of themes was based on 
consensus discussion between two researchers (KL and 
FB), and was supported by NVivo software (V.11 QSR 
2008). Main themes and subthemes were first identified 
in relation to separate participants, and then across the 
whole sample. The qualitative analysis was supervised by 
LM.
Patient and public involvement
A former patient of the ketamine clinic was involved 
in reviewing and providing feedback on the interview 
schedule and participant information literature prior to 
submission to the local research ethics committee.
ReSulTS
Participants
In total, 40 current and past patients were approached (21 
females and 19 males). Eighteen individuals expressed 
initial interest in the study and 14 (35%, 8 females and 
6 males) went on to participate. Of the 4/18 patients 
who did not go on to take part, three did not respond 
to invitations to meet with the researcher and one with-
drew before the informed consent process. One of the 
final 14 participants had stopped treatment 16 months 
prior to commencement of the study (22 months prior 
to interview) due to non-response but was included in 
the sample to ensure a range of perspectives. Partici-
pants were predominantly White British (13/14), with 
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Table 1 Characteristics of the participants (n=14)
Characteristics n=14
Gender (male/female) 6/8
Age (years) 24–64; median 41
Past self-harm 8
Family history of self-harm or suicide 4
BDI suicidal ideation score*
  At commencement of treatment 1 n=7
2 n=5
3 n=2
  At interview 0 n=6
1 n=4
2 n=3
3 n=1
*= 0=No thoughts of killing self; 1=Thoughts of killing self, but 
would not carry them out; 2=Would like to kill self; 3=Would kill self 
if had the chance
BDI, Beck Depression Inventory.
Table 2 Impact of ketamine on suicidal ideation (SI) in 
those patients who experienced benefit (n=12)
Onset of reduced SI n=12
Immediate/during treatment 2
Within an hour of treatment 5
A few hours after treatment 2
A day or more after treatment 3
Duration of reduced SI   
0–24 hours 2
Several days 4 (3–6 days)
A week or more 0
A month or more 1
Ongoing 5
one classed as White Other. Ages ranged from 24 to 64 
years, with a median age of 41 years. Most (11) partici-
pants lived with others (spouses, partners, parents, house 
share, student accommodation), with three living alone. 
Six participants were registered as sick or disabled at the 
time of their interviews.
All 14 participants met criteria for treatment-resistant 
depression.5 Two had a primary diagnosis of bipolar 
affective disorder type 1, two a diagnosis of emotionally 
unstable personality disorder and the remaining 10 a 
primary diagnosis of depression. BDI scores for the SI 
question at the start of ketamine treatment and at inter-
view are shown in table 1.
Ketamine treatment
Ten participants were engaged in ongoing ketamine 
treatment at the time of interview. Of the remaining four, 
one had received ketamine a month prior to interview, 
two 9 months before and one 22 months prior to inter-
view. Reasons for cessation of treatment were non-re-
sponse (n=1), treatment becoming ineffective over time 
(n=1), severe side effects (n=1) and a lack of supply of 
oral ketamine (n=1).
There was considerable variation in the length of time 
participants were involved in treatment. Two individuals 
received between one and three infusions over a few 
weeks, five had between 6 and 88 infusions and up to 
199 oral doses over a year or more (19 months to 6 years, 
three consistently and two periodically). The length of 
treatment and number of doses for the remaining seven 
was somewhere between these points (3–6 infusions and 
up to 46 oral doses over 4–9 months).
Impact of ketamine on SI
Twelve participants reported a reduction in SI at some 
stage following ketamine treatment. The onset and dura-
tion of this effect varied; onset ranged from immediate 
to a day or more after treatment, and duration from less 
than 24 hours to 3 years with ongoing treatment (table 2). 
One patient who reported a reduction in SI had treat-
ment stopped after one infusion due to adverse side 
effects (see below). Of the two participants who did not 
report a reduction in SI, one did not experience any 
noticeable benefit from ketamine at all apart from a mild 
and transient improvement in mood; the other experi-
enced improved energy levels and cognitive function but 
only rarely any improvement in mood.
Four participants experienced sustained elimination of 
SI on both intravenous and oral ketamine.
And the strongest thing that’s come out of the ket-
amine is that it doesn’t matter how down I’ve got, af-
ter maybe the first one, maybe two, the idea of suicide 
is not there. (P3)
Two of these four participants (three of whom were 
receiving ketamine at the time of interview) noticed a 
return of SI during periods they were without treatment 
(between intravenous and oral treatment, or when they 
ran out of oral treatment), although stated that the idea-
tion was less intense.
[SI returned] Only when I’ve been off it for 
two months…. but not quite as bad as I’ve expe-
rienced it before… the fact that the thought had 
flashed into my mind at all was like, ah and now it’s 
time to get in contact. (P6)
Three participants experienced an elimination of 
SI following intravenous treatment, which lasted from 
6 hours to 9 months (6 hours; 6–8 days; 3–9 months). One 
of these participants had only ever received intravenous 
ketamine; the others had received both intravenous and 
oral treatment but experienced elimination of SI only 
with intravenous administration, although they reported 
a reduced intensity of SI on oral ketamine.
I thought if it doesn’t work, on the way back, because 
we were staying in a hotel, and I was going to kill my-
self there… I actually went and had dinner with my 
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dad in the hotel room on the way back, which I’ve 
never done before. Usually I wouldn’t be up to doing 
that mood wise. And I was able to eat and enjoy the 
food… [The oral] never had the impact of reducing 
the suicidal thoughts to the extent that the infusion 
did…. on the infusion they disappeared. (P8)
A further participant had only one full intravenous 
treatment before stopping due to side effects (exacer-
bated hallucinations and intrusive unpleasant and para-
noid thoughts), but reported a period of a few hours of 
relief from persistent SI on the third day after the first 
treatment, which they attributed to the ketamine.
A reduction in SI was reported by six participants, 
which manifested as a reduction in intensity rather than 
frequency, with content unchanged.
The intensity of the thought is definitely reduced…I 
can cope with the frequency, lots of them at a small 
level, I’m so used to them that it doesn’t bother me. 
But if I get lots at a high intensity, this is when things 
start to break down. So reducing the intensity is the 
first step for me. (P2)
The intravenous ketamine treatment was experienced 
as considerably stronger and, for most participants, more 
effective than oral treatment in reducing SI, although 
eight of the nine individuals who had oral treatment did 
report some benefit from it.
The oral dose, I suppose is stopping me from doing a 
suicide attempt even though I still have those suicidal 
feelings …it lessened the intensity of them so I would 
think I’ll hold on for a bit longer and see what, think-
ing more of other people. (P8)
Notwithstanding the greater effect of intravenous keta-
mine, one participant preferred the regime of having 
the more regular, although lower, doses permitted by 
taking ketamine orally. Another favoured oral treatment 
because, although it did not eradicate SI as the intrave-
nous treatment did, there was not such a significant drop 
in mood when the effects wore off and improved func-
tionality was more sustained.
Dissociative and euphoric effects
Dissociative effects during ketamine treatment were 
experienced some or all of the time by the 12 partici-
pants who reported a positive impact on SI (and also by 
the two participants who did not experience reduced 
SI). For one participant, who went on to stop treatment 
due to side effects, this was experienced as malevolent 
hallucinations and an acute increase in pre-existing 
intrusive and disturbing thoughts and mental images. 
These effects continued for 2 days after treatment and 
the participant reported a sustained worsening of the 
pre-existing thoughts and images even at the point of 
interview. Dissociative effects were more common and 
stronger with intravenous treatment and one participant 
reported no dissociative effects at all with oral treatment. 
To describe the difference one participant likened the 
oral ketamine to drinking a glass of wine and the intrave-
nous to consuming a bottle of vodka.
Participants were not asked specifically if they thought 
the reduction in their SI was linked to the dissociative 
effects they experienced. However, when asked if they 
had discovered ways of maximising the overall benefit 
of ketamine, five participants said they would take oral 
ketamine on an empty stomach to achieve a stronger 
sense of dissociation and derive more benefit, suggesting 
they believed there was such a link, although two partic-
ipants noted that in practice this was not always the case.
Sometimes I won’t get as much of a kick from taking 
it, almost not notice … and I’m like did I get any? … 
and then the next week will be fine. Sometimes I’d get 
a really powerful thing and the next week felt down, 
so there was definitely some stuff going on there that 
was beyond my ability to make sense of. (P6)
One participant reported getting the giggles and feeling 
like a ‘happy drunk’ during intravenous ketamine treat-
ment and two others described clear euphoric effects.
It was like a weight had been lifted off my shoulders. 
It was like I’d let go of a big weight, like a heavy weight 
had shifted from me. It was absolutely amazing. (P1)
These three participants all experienced an eradication 
of SI following ketamine infusions. For two this was tran-
sitory and for one it was longer lasting (for some months 
following a course of four infusions).
Other side effects
All participants experienced some side effects, including 
the effects during ketamine administration, ranging from 
rarely to always (the most frequently reported of which 
were feeling strange or unreal (n=14), abnormal sensa-
tions such as seeing or hearing unusual things (n=11), 
tiredness (n=11), blurred vision (n=8) and headaches 
(n=7)). One participant reported severe side effects 
resulting in cessation of treatment (see above). For the 
rest of the participants (n=13), however, side effects were 
not considered major and six explicitly stated that the 
side effects they experienced from ketamine were much 
less severe than those they had experienced with conven-
tional antidepressants. No participant described an asso-
ciation between side effects and impact of ketamine on 
SI, nor did any individual require prescribed medication 
to address side effects.
Perceived mechanisms contributing to reduced SI
Participants rated the frequency with which they expe-
rienced benefits following ketamine treatment using 
a structured checklist (table 3). Of the 12 participants 
whose SI was reduced by ketamine, five reported that they 
always experienced a reduction in SI following treatment, 
although improved mood, reduced anxiety and increased 
energy were experienced less regularly. This suggests that 
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Table 3 Participants’ responses regarding specific impacts 
of ketamine
Participants with 
reduced suicidal 
ideation (n=12)
Participants with no 
reduction in suicidal 
ideation (n=2)
Ketamine reduced suicidal ideation
Always 5*
Often 5
Sometimes 2
Never 2
Ketamine improved mood
Always 3* 1
Often 7
Sometimes 2 1
Ketamine reduced anxiety
Always 2*
Often 8 1
Sometimes 1
Rarely 1
Never 1
Ketamine increased energy levels
Always 2
Often 5 1
Sometimes 5*
Rarely 1
*One of these participants had only one full intravenous treatment 
due to severe side effects.
Figure 1 Participants’ perspectives of mechanisms 
associated with reduced suicidal ideation (SI) (n=12).
in some cases SI was reduced independently of mood and 
anxiety.
I think it’s separate [from mood]. Because there’s 
still days where I feel very low and normally the sui-
cide thing would be at the back of my head or be 
there, but it, without any thought process, it’s gone, 
and I can’t reason that one. (P3)
Themes derived from participants’ narratives reflect the 
checklist findings and indicate that while improved mood 
and reduced anxiety were both associated with a reduc-
tion in SI, clarity of thought, improved focus and concen-
tration, and improved ability to function were additional 
factors involved in the alleviation of SI (figure 1; table 4). 
These perceptions were consistent across the sample, and 
accounts of individuals with diagnoses of bipolar disorder 
or emotionally unstable personality disorder did not 
appear to differ from those of participants with a primary 
diagnosis of depression.
Participants reported similar perceptions of the mecha-
nisms involved in reduction of SI but some differences in 
experiences of order of occurrence. Most (n=8) perceived 
that an improvement in mood resulted in reduced SI, but 
for others the improvement in mood was itself a result of 
improved clarity of thought and the associated ability to 
focus.
I think it may be more ways, not necessarily my mood, 
maybe that I could have a gap in thinking without the 
thoughts coming in. So I could distract and therefore 
look at other things that could help my mood, which 
then I suppose reduces the suicidality, because when 
the mood goes really low I can’t concentrate on any-
thing or think about other things. So basically, the 
ketamine helps to give you a different perspective at 
looking outwards and being interested in different 
things so I’m not being wound in constant thoughts. 
(P8)
Improved clarity of thought was experienced by some 
participants (n=7) as a reduction in intrusive thoughts or 
depressive ruminations. Such thoughts were negative and 
frequently suicidal in nature and described as ‘constant 
thoughts’, ‘tornado of thoughts’, ‘rapid fire thoughts’, ‘head 
swimming’ and ‘ruminations’.
The day after [ketamine treatment] I maybe have 
more clarity of thought. I think instead of maybe 
being so locked into the pattern of kind of cyclical 
thinking and rumination, I think it does maybe break 
that up a bit and maybe make you a bit more open to 
possibilities (P4)
Other participants (n=3) described a process of making 
sense of thoughts and reaching new understandings or 
gaining new perspectives. Two of these participants used 
the same metaphor (‘it’s like rinsing my brain out’, ‘it’s like 
having your brain jet washed’) to describe this experience. 
The remaining two participants experienced a relief 
from slowed thinking and used the same descriptors for 
their state before treatment with ketamine (‘nothingness’, 
‘this blank nothing’) and the metaphor of ‘the fog lifting’ 
to describe how they felt ketamine enabled clarity of 
thought.
6 Lascelles K, et al. BMJ Open 2019;9:e029108. doi:10.1136/bmjopen-2019-029108
Open access 
Table 4 Key themes, subthemes and perceived impact of subthemes
Main themes Subthemes Perceived subthemes
1. Clarity of thought Reduced intrusive thoughts
Relief from slowed thoughts
Reaching new understandings
Getting a break
2. Focus and concentration Able to make decisions
Motivation and energy
Choosing not to act on SI
Able to let go
Seeing other options
3. Ability to function Activities of daily living
Socialisation
Doing normal stuff
Improved connection with others
SI, suicidal ideation.
Ketamine’s positive effect on anxiety was noticed 
by most participants who experienced a reduction in 
SI (n=11/12). Some put this down to the reduction in 
intrusive negative and suicidal thoughts whereas others 
described a general reduction in anxiety that was asso-
ciated with improved ability to focus, which in turn 
prevented intrusive thoughts.
It’s linked with the focus right, so if you’re focused on 
your task or what’s in front of you at the time, there’s 
no place for neurotic and other thoughts to kick in 
and actually then lead you to suicidal thoughts. (P12)
Clarity of thought and the ability to focus along with 
increased energy levels were linked to improved function-
ality in relation to activities of daily living and socialisation.
By the thoughts being slowed down you automatically 
gain more control because you can isolate them…ev-
erything seems more manageable at a slower pace… 
the mood is able to go up and the suicidal thinking 
comes down… It means I can do things. I can get out 
of bed. I can take my kids to school. I can have a show-
er… (P2)
Although participants were not specifically prompted 
about hopelessness, some accounts suggested that this 
reduced somewhat as mood improved and the treatment 
was experienced as being effective, for example:
I think it’s because my mood improved and I had a 
reason to keep going. There wasn’t this black hole 
that was always going to be there. And, you know, as 
soon as somebody says ‘well you’re drug resistant to 
this’ you do, you go oh, bloody hell. So that’s it. (P7)
Self-harm
Two of the 14 study participants had self-harmed while 
undergoing ketamine treatment. One of these reported 
an overall reduction in intensity of SI. A third participant, 
who had ketamine periodically over some years, had 
episodes of self-harm when in a mental health crisis, while 
not receiving ketamine, which led to further courses 
of ketamine treatment. A fourth participant had self-
harmed since cessation of ketamine treatment (due to 
side effects). All of these participants had a history of self-
harm prior to commencement of ketamine treatment.
DISCuSSIOn
In this study we explored patients’ accounts of the 
impact of ketamine treatment on their suicidal thinking 
and perspectives of the associated mechanisms. Treat-
ment with ketamine was reported as reducing SI in 12 
out of 14 participants. However, the intensity and dura-
tion of effects on SI varied greatly. In most clinical trials 
which have shown an impact of a single treatment with 
ketamine on SI, this effect has not usually persisted 
beyond 72 hours,13 21 22 although has had longer effects 
in some patients. In the present study, some participants 
who reported benefits in terms of reduced SI identified 
a relatively long duration of effect. Grunebaum et al12 
found an effect on SI up to 6 weeks following a single 
infusion of ketamine.12 Also, in our study all but one indi-
vidual had received multiple ketamine treatments. Some 
of these reported that beneficial effects on SI persisted 
with continuation of treatment, but that this effect was 
lost if treatment was discontinued.
Differences between individual experiences of impact 
of ketamine on suicidality have been noted by other 
authors, such as Ballard et al18 who found that those least 
likely to have reduced SI following ketamine were those 
with the most severe SI and a history of self-injury.18 Of 
the eight participants in our study who scored 2 or above 
in the BDI SI question, six had a history of self-harm. Five 
of these reported a beneficial impact on SI; one complete 
elimination, two elimination with ketamine infusion and 
reduction with oral treatment and two an overall reduc-
tion. These findings indicate that most participants who 
had stronger SI and a history of self-harm experienced a 
reduction in SI following ketamine treatment. The rest 
of the participants (n=6) had less severe SI and fewer 
(n=2) had a history of self-harm. However, responses of 
this group were similar to the group with higher SI; one 
reported no response; two reduced SI; and three elimina-
tion of SI.
One possibility for optimising improvement in thought 
processes and functionality experienced following 
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ketamine treatment, and hence longer term benefits 
for both depression and SI, could be additional use of 
intensive psychological therapy. Some participants in this 
study spontaneously mentioned the need for psycholog-
ical treatment and the fact that ketamine made them 
feel more amenable to therapy or more able to use skills 
learnt in previous therapy. Repeated treatment with 
ketamine, as was the case for several participants in this 
study, is another approach.
Previous research has indicated that a single dose of 
ketamine has a short-term positive effect on hopelessness 
as well as SI.23 24 In our study some participants’ accounts 
suggested that reduced hopelessness was experienced 
alongside or subsequent to improvement in mood and 
due to the relief of finding a treatment that was more 
effective than those previously tried. However, hopeless-
ness was not systematically explored in this study.
Potential mechanisms of impact of ketamine on SI
Participants’ accounts indicated that they regarded the 
beneficial effects of ketamine on SI to be partly related 
to improvements in depression and anxiety. However, 
some also related the impact on SI to improved clarity of 
thinking and functionality. This is in keeping with find-
ings from other studies that improvements in SI following 
a single treatment with ketamine can occur partly inde-
pendently of improvements in mood, with improvement 
in depression explaining about 50% of the improvement 
in SI.12 13 Grunebaum et al12 found that reduced SI largely 
continued up to 6 weeks after infusion and explained that 
this is likely to be partly due to concomitant treatment 
with other psychotropic medication, although the partici-
pants were not necessarily suffering from treatment-resis-
tant depression.12
Research implications
The variety of responses found in this study and other 
investigations indicate that measures of impact should 
be monitored frequently in trials assessing the impact of 
ketamine on SI and behaviour. Further work is needed to 
try to identify likely responders. This will be particularly 
important should ketamine be used for management of 
SI in emergency situations. Our findings, and those of 
others,12 18 suggest that there should be more focus on 
investigating the mechanisms involved in beneficial effects 
of ketamine on SI. We would encourage deployment 
of mixed-methods studies, including nested qualitative 
studies within RCTs, for this purpose and for obtaining a 
more nuanced appraisal of the effects of ketamine than 
may be possible by only using scales to assess impact.
Strengths and limitations
We are unaware of previous qualitative studies of the 
experiences of depressed patients with suicidal ideas 
receiving treatment with ketamine. The approach we 
have used encourages a real-world appraisal of the 
impact of ketamine and allows highlighting of individual 
patients’ experiences. However, there are limitations, 
especially in terms of the small sample size and the poten-
tial lack of generalisability associated with the qualitative 
methodology. In addition, participants who responded 
to invitations to participate were self-selected and there 
may be some bias in terms of those agreeing to partici-
pate perhaps having experienced a more positive impact 
on their SI than those who declined. The inclusion 
criteria included a positive score on a single item on a 
mood scale, the Beck Depression Inventory. Differences 
in response to ketamine in terms of SI have been found 
when different measures of SI have been used.13 The 
participants all attended a single clinic, which may also 
influence the generalisability of the findings. Further-
more, the interviews were conducted retrospectively and 
at varying times following initiation of treatment, with 
some participants still receiving ketamine and others 
having ceased treatment.
COnCluSIOnS
This study of patients’ experiences of treatment with 
ketamine has indicated variable responses in terms of 
changes in SI, both in intensity and duration of benefits. 
The patients’ perceptions of mechanisms involved in a 
reduction of SI suggest that improvements in depression 
and anxiety are just part of the effect, with improved 
clarity of thinking and functionality also being important. 
Further studies of patients’ experiences are warranted, 
especially in terms of understanding variability of effects 
of ketamine on suicidality, including hopelessness and 
actual suicidal behaviour, and how benefits of the medica-
tion might interact with activities of daily living and other 
treatments, including possible psychological therapy. 
Such work should add to knowledge about the suitability 
of use of ketamine to treat suicidality, especially in poten-
tial emergency situations. In addition, while we cannot 
comment on the effect of ketamine on repeat self-harm 
of people with emotionally unstable personality disorder, 
given that individuals with this diagnosis are in receipt of 
ketamine treatment such study would be judicious.
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